




Section 1Performance Report for FY2022 Q3

FY2022 Q3: Performance Highlights

All business segments remained steady. In particular, the core business segment, the use of data for industry, is expanding well.




FY2022 Q3: Summary of Consolidated Performance

Performance figures are steady in all categories.

(Unit: Million JPY)	FY2021 Q3	FY2022 Q3	Y-o-Y
Revenue	15,679	19,542	+25%
Operating profit (rate)	3,405 (22%)	4,028 (21%)	+18%
Profit before taxes (rate)	3,396 (22%)	4,007 (21%)	+18%
Profit attributable to owners of parent (rate)	2,272 (15%)	2,654 (14%)	+17%
EBITDA (margin)	4,580 (29%)	5,332 (27%)	+16%

FY2022 Q3: Consolidated Revenue/EBITDA

Revenue growth was solid even compared to the previous Q3, which performed strongly. On the other hand, profits were slightly lower due to the investment load for growth. The high profitability of existing businesses remained unchanged, but this was due to the intensification of activities aimed at becoming No. 1 in all healthcare data areas.



[Reference] FY2022 Q3: Consolidated Revenue/EBITDA (LTM Basis)


On a LTM basis, which excludes seasonality, both revenue and EBITDA are growing steadily.


The profit growth curve is expected to rise significantly in the future as data acquisition in new areas progresses and the No 1 position in multiple areas is established.



LTM Trends of Consolidated EBITDA

(Unit: Million JPY) (Unit: Million JPY)






FY2022 Q3: Performance by Segment


Revenues and profits increased in all segments.

(Unit: Million JPY)		FY2021 Q3	FY2022 Q3	Y-o-Y
Healthcare-Big Data	Revenue EBITDA (Margin)	9,883 3,412 (35%)	13,144 4,022 (31%)	+33% +18%
Tele-medicine	Revenue EBITDA (Margin)	3,370 1,200 (36%)	3,799 1,416 (37%)	+13% +18%
Dispensing Pharmacy Support	Revenue EBITDA (Margin)	2,567 209 (8%)	2,788 310 (11%)	+9% +48%
Adjustment	Revenue EBITDA	-143 -242	-189 -417	-

[Reference] FY2022 Q3: Revenue/EBITDA by Segment

Healthcare-Big Data Business generates more than 60% of JMDC Group's revenue and more than 70% of its EBITDA. Tele-medicine Business also continues to be highly profitable due to enhanced operational capabilities.






Section 2Healthcare-Big Data Business




Healthcare-Big Data Business: Performance

Revenue and EBITDA in Healthcare-Big Data Business continue to grow steadily, despite active investment and expansion of business areas to acquire new datasets.








For Industry: Business Status of Data Utilization

The scale of business is growing steadily, exceeding the high hurdles of the previous Q3, as data-driven consulting services continue to diversify. In addition, LTM to December continued to grow strongly at +34% Y-o-Y.



For Payers, Individuals, and Medical Service Providers: Status of Business


The business for payers and individuals grew thanks to the expanding provision of solutions through Pep Up, which more than compensated for the decline in sales of wearables. The business for medical service providers is also expanding rapidly, thanks to increased resources and expanded services through new business investments.


(Unit: Million JPY)

Quarterly Revenue Trends of Business for Payers/Individuals

Quarterly Revenue Trends of Business for Medical Service Providers

(Unit: Million JPY)





Section 3

Tele-medicine Business and Dispensing Pharmacy Support Business



Tele-medicine Business: Performance


Although partially affected by Covid-19, business performance continues to show steady growth as operational capabilities have been strengthened.


(Unit: Million JPY)

Quarterly Revenue Trends of Tele-medicine Business

Quarterly Trends of EBITDA

(Unit: Million JPY)





Dispensing Pharmacy Support Business: Performance


Both revenue and profit are stable, though still partly affected by investment restraints in dispensing pharmacies.


(Unit: Million JPY)

Quarterly Revenue Trends of Dispensing Pharmacy Support Business

Quarterly Trends of EBITDA

(Unit: Million JPY)





AppendixBusiness Outlook




"Providing a Healthy and Rich Life for All Individuals"

Leveraging data and ICT solutions to create a sustainable healthcare system


Future Policies

We will expand our data and business areas in an ecosystem where we provide data-driven services in various areas in the healthcare industry, receive data returns, and further evolve our services.




Whole Patient care using data

JMDC will use the power of data and ICT to advance business so that it brings the optimal and satisfactory medical care to all people.



Balance of Businesses According to Customers

JMDC engages in businesses for any type of healthcare industry player in a well-balanced manner by carrying out diverse business activities.



This document is intended to provide corporate and other information concerning JMDC Inc. ("JMDC") and its group. It is not intended to solicit people for acquisition of shares and securities issued by JMDC, either in Japan or any other country.

Forward-looking statements in this document, including the JMDC Group's goals, plans, estimates, and forecasts, merely reflect decisions or ideas of the JMDC Group as of the time of writing. The actual results of the Group, including operating results and financial position, may vary greatly from the content of this document and assumptions based on the content depending on the economic situation at home and abroad, industrial trends, business competition, securing of human resources, technical innovation, and other factors of the business environment.

The information described in this document concerning the industry, market trends, economic situation, etc. was prepared based on the information available as of the time of writing and the JMDC Group provides no warranty as to the authenticity, accuracy, reasonableness, and completeness of such information. The information regarding other companies, etc., described in this document is quoted from public information or data prepared by third parties, and JMDC has not independently verified and does not guarantee the accuracy and appropriateness of such information. In addition, this document may describe information based on the JMDC Group's judgment, forecast, or estimation about the industry, market trends, economic situations, etc. Such information, however, merely reflects decisions or ideas as of the time of writing and the actual values may greatly differ from the information. The information regarding potential profit-earning opportunities for JMDC Group in this document is only an indication of the potential (scale) of future profit-earning opportunities that JMDC currently assumes based on certain assumptions, and does not represent our forecast, plan, estimate, or target for our performance at a specific point in the future. In addition, actual results may differ materially from those described in this document.

Financial data and other indicators of other companies cannot be directly compared with the corresponding indicators of JMDC due to differences in accounting standards, calculation methods, etc. Future changes in circumstances may affect the content of this document, however, JMDC takes no responsibility for updating or correcting this document. The content of this document is subject to change without prior notice.

